All Stories

  1. Atezolizumab for the treatment of breast cancer

    Article • Expert Opinion on Biological Therapy, May 2018, Taylor & Francis

    Professor Fabio Puglisi, Fabio Puglisi

  2. Efficacy and safety of eribulin in taxane-refractory patients in the ‘real world’

    Article • Future Oncology, May 2017, Future Medicine

    Professor Fabio Puglisi, Fabio Puglisi

  3. Caring for cancer survivors: perspectives of oncologists, general practitioners and patients in Italy

    Article • Future Oncology, February 2017, Future Medicine

    Professor Fabio Puglisi, Fabio Puglisi

  4. Bevacizumab in breast cancer

    Article • Future Oncology, November 2016, Future Medicine

    Prof. Paolo Marchetti, Professor Fabio Puglisi, Fabio Puglisi

  5. Real-time tests of multiple genome alterations take the first steps into the clinic: a learning example

    Article • OncoTargets and Therapy, August 2016, Dove Medical Press

    Professor Fabio Puglisi, Fabio Puglisi

  6. Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients' heart?

    Article • OncoTargets and Therapy, September 2014, Taylor & Francis

    Dr Chiara Lestuzzi, Dr MARIA GRAZIA BALDIN, Professor Fabio Puglisi, Fabio Puglisi